CRISPR-based gene editing company SNIPR Biome has secured USD 5.48 million from global non-profit partnership Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X).
The proceeds are to be used to fuel the Phase Ib/IIa clinical trial for SNIPR001, a CRISPR-armed phage therapeutic that targets the prevention of E. coli bloodstream infections in hematological cancer patients who are undergoing hematopoietic stem-cell transplantation (HSCT). The trial is expected to commence later this year, involving around 24 patients across 10 sites in Europe and the US.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.